A federal advisory panel voted Thursday to soften rules on seven peptides, including BPC-157 and TB-500. The vote was close. It is advisory only. The FDA has given no signal on whether it will adopt the suggestion. The move came after weeks of stakeholder sessions. Wellness backers advocated aggressively for wider access. RFK Jr. was among them. Critics say these compounds have no solid safety track record or help for most uses. The call could reshape how the agency handles a part of the wellness market that is growing very fast. Watchers are waiting to see if the FDA picks up the plan. A spokesperson for the regulator offered no deadline for a follow-up. Industry voices argue the change would open up access to products users find useful. Skeptics warn that looser rules could open the door to misuse across a fast-moving market. The advisory vote only opens the door to a change, and the final say rests with the federal regulator.